Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  gemtuzumab ozogamicin
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 48 for your search:
Start Over
Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Completed
Age: 18 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: 0903X-100847, NCT00161668
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: LAP-R2007, NCT00504764
LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Any age
Sponsor: Other
Protocol IDs: PETHEMA-LAM07, NCT01041040
Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 65
Sponsor: Other
Protocol IDs: MYFLAI07, NCT00909168
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
Phase: Phase III
Type: Treatment
Status: Closed
Age: 16 to 60
Sponsor: NCI, Other
Protocol IDs: CDR0000258113, U10CA021115, E1900, ECOG-1900, NCT00049517
Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia
Phase: Phase III
Type: Treatment
Status: Completed
Age: 61 to 75
Sponsor: Other
Protocol IDs: EORTC-06012, AML-17, GIMEMA-AML-17, NCT00052299
S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: NCI, Other
Protocol IDs: CDR0000360812, U10CA032102, S0106, SWOG-S0106, NCT00085709
Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Phase: Phase III
Type: Treatment
Status: Closed
Age: 61 and over
Sponsor: Other
Protocol IDs: CDR0000433422, SAKK-AML-43, EU-20514, HOVON-AML-43, NCT00121303
Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
Phase: Phase III
Type: Treatment
Status: Completed
Age: 21 and under
Sponsor: NCI, Other
Protocol IDs: AML02, 5R01CA113482, NCT00136084
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Treatment
Status: Closed
Age: Under 30
Sponsor: NCI, Other
Protocol IDs: AAML0531, COG-AAML0531, CDR0000487497, NCT00372593
S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: S0521, U10CA032102, SWOG-S0521, NCT00492856
NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and under
Sponsor: Other
Protocol IDs: NOPHO-AML 2004, NCT00476541
Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 60
Sponsor: Other
Protocol IDs: BRD 06/10-I, NCT00860639
A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old
Phase: Phase III
Type: Treatment
Status: Completed
Age: 50 to 70
Sponsor: Other
Protocol IDs: ALFA 0701, NCT00927498
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 55 to 75
Sponsor: Other
Protocol IDs: ID01-010, NCT00038831
A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: KAN-979-02, NCT00233909
Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 90
Sponsor: Other
Protocol IDs: 090516, NCT00766116
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 50 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01147, IR-6921, CDR0000642213, 2288.00, 8297, P30CA015704, FHCRC-2288.00, NCT00895934
Bendamustine Hydrochloride and Idarubicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 60 and over
Sponsor: NCI, Other
Protocol IDs: 2413.00, NCI-2010-01253, K12CA076930, NCT01141725
CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: W-AR-0903B1-201-US, CDR0000065896, UCCRC-8600, NCI-V97-1355, NCT00003131
CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse
Phase: Phase II
Type: Treatment
Status: Completed
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: W-AR-0903B1-203-US, CDR0000066771, NCI-V98-1497, NCT00003673
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067944, E-4999, NCT00005962
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 61 and over
Sponsor: Other
Protocol IDs: EORTC-06993, EORTC-06993-AML-15, NCT00006122
Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase II
Type: Treatment
Status: Completed
Age: 17 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068208, U10CA031946, CALGB-19902, NCT00006265
Start Over